Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?
Androgen deprivation therapy (ADT) is the longstanding treatment for advanced prostate cancer (PC) because androgen receptor (AR) is the key therapeutic vulnerability for this disease. Bipolar androgen therapy (BAT) — the rapid cycling of supraphysiologic androgen (SPA) and low serum testosterone le...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Clinical Investigation
2022-12-01
|
| Series: | The Journal of Clinical Investigation |
| Online Access: | https://doi.org/10.1172/JCI165357 |